United States Copper Index Fund vs Ginkgo Bioworks Holdings Inc — how do they compare? United States Copper Index Fund trades at $39.91 (market cap $716.81M), while Ginkgo Bioworks Holdings Inc trades at $11.59 (market cap $772.39M). The key difference: United States Copper Index Fund and Ginkgo Bioworks Holdings Inc are close in size by market cap, and United States Copper Index Fund is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| CPER | DNA | |
|---|---|---|
Market Cap | $716.81M | $772.39M |
Volume | 388,730 | 6,453,273 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $15.83 |
52-Week Low | $30.27 | $5.48 |
Typical Hold Time | 48 Days | 7 Days |
Enterprise Value | — | $874.34M |
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →